In patients developing overt diabetes, most common flow-charts suggest metformin as a first-line therapy and, whether abnormal glucose profile persists, a GLP-1 receptor agonist (GLP1-RA) or a dipeptidyl-peptidase-4 inhibitor (DPP4-i). The gene discussed is DPP4; the disease is diabetes mellitus.